Company intelligence / Profile preview
Avilar Therapeutics
Waltham, Massachusetts, United Statesavilar-tx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Avilar has presented preclinical data for their ATAC extracellular protein degraders at the Targeted Protein Degradation Summit in 2023 and preclinical proof-of-concept data for their MTAC protein degrader platform at IMMUNOLOGY 2024[6][9].
- Therapeutic areas
- ImmunologyInfectious Diseases
- Modalities
- Protein degraders (ATACs - ASGPR Targeting Chimeras, MTACs - M6PR Targeting Chimeras)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Avilar Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avilar Therapeutics.